Mallinckrodt to divest BioVectra for £202m

This article was originally published here

The deal includes a fixed consideration of $175m (£141m), comprised of an upfront payment of $135 (£109m) and a long-term note for $40m (£32m), as well as contingent

The post Mallinckrodt to divest BioVectra for £202m appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply